{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T19:18:41Z","timestamp":1777922321950,"version":"3.51.4"},"reference-count":44,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Monoclonal Antibodies in Immunodiagnosis &amp; Immunotherapy"],"published-print":{"date-parts":[[2015,6]]},"abstract":"<jats:p>\n                    Breast cancer is a major public health problem worldwide. Although in Iran cancer is the third cause of death after coronary heart disease and accidents, mortality from cancer has been on the rise during recent decades. About 15% to 20% of patients with invasive breast cancer have abnormally high levels of HER2 protein. HER2 is a specialized protein found on breast cancer cells that controls cancer growth and spread. This study describes the generation and characterization of new anti-HER2 MAbs towards HER2 protein using a chimeric peptide immunogen containing discontinuous B-cell epitope peptide (peptide 626) and promiscuous T-helper epitope (MVF). The specificity of these MAbs was confirmed in various immunoassays, including ELISA, Western blotting, and immunofluorescence. Moreover, the MTT assay results indicated that 5H5 and 5H\n                    <jats:sub>11<\/jats:sub>\n                    MAbs could reduce the growth of SKBR3 cells by approximately 50% (\n                    <jats:italic toggle=\"yes\">p<\/jats:italic>\n                    &lt;0.05). These MAbs that can reduce cancer cell proliferation would be useful for cancer therapy. Furthermore, the synthetic peptide used in the current work was able to induce the immune system to generate antibodies, especially IgG isotype. Therefore, it could be further used as a peptide cancer vaccine that targets different epitopes or structural domains of HER2 ECD.\n                  <\/jats:p>","DOI":"10.1089\/mab.2014.0092","type":"journal-article","created":{"date-parts":[[2015,6,19]],"date-time":"2015-06-19T15:06:21Z","timestamp":1434726381000},"page":"213-221","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":7,"title":["Production and Characterization of New Anti-HER2 Monoclonal Antibodies"],"prefix":"10.1177","volume":"34","author":[{"given":"Manijeh","family":"Mahdavi","sequence":"first","affiliation":[{"name":"Isfahan University of Medical Sciences","place":["Iran"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehrnaz","family":"Keyhanfar","sequence":"additional","affiliation":[{"name":"University of Isfahan","place":["Iran"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abbas","family":"Jafarian","sequence":"additional","affiliation":[{"name":"Isfahan University of Medical Sciences","place":["Iran"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hassan","family":"Mohabatkar","sequence":"additional","affiliation":[{"name":"University of Isfahan","place":["Iran"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Rabbani","sequence":"additional","affiliation":[{"name":"Isfahan University of Medical Sciences","place":["Iran"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2015,6]]},"reference":[{"key":"e_1_3_3_2_2","unstructured":"Breast cancer epidemiology. Medical News. http:\/\/www.news-medical.net\/health\/Breast-Cancer-Epidemiology.aspx"},{"key":"e_1_3_3_3_2","unstructured":"Breast cancer incidence statistics. Cancer Research UK. http:\/\/www.cancerresearchuk.org\/cancerinfo\/cancerstats\/types\/breast\/incidence\/uk-breast-cancer-incidence-statistics"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1186\/bcr2261"},{"key":"e_1_3_3_5_2","unstructured":"Breast cancer statistics. Cancer Australia. http:\/\/canceraustralia.gov.au\/affected-cancer\/cancer-types\/breast-cancer\/breast-cancer-statistics"},{"issue":"2","key":"e_1_3_3_6_2","first-page":"143","article-title":"Five common cancers in Iran [minireview]","volume":"13","author":"Kolahdoozan S","year":"2010","unstructured":"Kolahdoozan S, , Sadjadi A, , Radmard AR, , and Khademi H: Five common cancers in Iran [minireview]. Arch Iran Med, 2010; 13(2):143\u2013146.","journal-title":"Arch Iran Med"},{"issue":"9","key":"e_1_3_3_7_2","first-page":"361","article-title":"Incidence and screening of breast cancer in Iranian women","volume":"10","author":"Hashemian M","year":"2013","unstructured":"Hashemian M, , Ghardashi F, , Asadi Z, , Khosroabadi A, , Pejhan A, , Javan R, , and Nakhaei MR: Incidence and screening of breast cancer in Iranian women. Life Sci J, 2013; 10(9s):361\u2013366.","journal-title":"Life Sci J"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1593\/neo.04313"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M311153200"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603581"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1535-6108(02)00039-9"},{"issue":"3","key":"e_1_3_3_12_2","first-page":"560","article-title":"Down-regulation of HER2\/neu expression induces apoptosis in human cancer cells that overexpress HER2\/neu","volume":"60","author":"Roh H","year":"2000","unstructured":"Roh H, , Pippin J, , and Drebin JA: Down-regulation of HER2\/neu expression induces apoptosis in human cancer cells that overexpress HER2\/neu. Cancer Res, 2000; 60(3):560\u2013565.","journal-title":"Cancer Res"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1021\/mp9002514"},{"key":"e_1_3_3_14_2","unstructured":"FDA: FDA approves Perjeta for neoadjuvant breast cancer treatment. U.S. Food and Drug Administration. http:\/\/www.fda.gov\/newsevents\/newsroom\/pressannouncements\/ucm370393.htm"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2010.04.009"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/12.suppl_1.S3"},{"issue":"4","key":"e_1_3_3_17_2","first-page":"1831","article-title":"Localization of a major receptor-binding domain for epidermal growth factor by affinity labeling","volume":"8","author":"Lax I","year":"1988","unstructured":"Lax I: Localization of a major receptor-binding domain for epidermal growth factor by affinity labeling. Mol Cell Biol, 1988; 8(4):1831\u20131834.","journal-title":"Mol Cell Biol"},{"issue":"12","key":"e_1_3_3_18_2","first-page":"2435","article-title":"HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells","volume":"10","author":"Pietras RJ","year":"1995","unstructured":"Pietras RJ: HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene, 1995; 10(12):2435\u20132446.","journal-title":"Oncogene"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.2885917"},{"key":"e_1_3_3_20_2","unstructured":"Garrett JT Kaumaya P Pei D and Dalbey R: Peptide based B cell epitope vaccines targeting HER-2\/Neu. 2007. Dissertation Ohio State University."},{"key":"e_1_3_3_21_2","unstructured":"Jones A and Kaumaya P: Peptide vaccines against the HER-2\/neu dimerization loop. 2006. Dissertation Ohio State University."},{"key":"e_1_3_3_22_2","first-page":"1250","article-title":"Trastuzumab: mechanisms of resistance and therapeutic opportunities","volume":"22","author":"Calabrich A","year":"2008","unstructured":"Calabrich A, , Fernandes GS, , and Katz A: Trastuzumab: mechanisms of resistance and therapeutic opportunities. Oncology, 2008; 22:1250\u20131258.","journal-title":"Oncology"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncponc0509"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncponc1156"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.184"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1535-6108(02)00097-1"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-03-3856"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-4597"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1186\/1756-9966-29-23"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.1994.tb02079.x"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2003.09.012"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.7314\/APJCP.2012.13.7.3053"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.7314\/APJCP.2013.14.10.5973"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-6-223"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-9-71"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13277-014-2503-y"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-1759(03)00081-4"},{"key":"e_1_3_3_38_2","volume-title":"Current Protocols in Immunology","author":"Yokoyama WM","year":"1995","unstructured":"Yokoyama WM: Production of monoclonal antibodies. In: Current Protocols in Immunology. John Wiley & Sons, New York, 1995."},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1080\/15321810701735161"},{"key":"e_1_3_3_40_2","volume-title":"Current Protocols in Immunology","author":"Hornbeck P","year":"1991","unstructured":"Hornbeck P: Enzyme-linked immunosorbent assays. In: Current Protocols in Immunology. John Wiley & Sons, New York, 1991."},{"key":"e_1_3_3_41_2","unstructured":"Roche lab techniques. http:\/\/www.roche-applied-science.com\/"},{"key":"e_1_3_3_42_2","first-page":"3782","article-title":"Prevention of mammary tumours with a chimeric Her-2 B-cell epitope peptide vaccine","volume":"60","author":"Dakappagari NK","year":"2000","unstructured":"Dakappagari NK, , Douglas DB, , Triozzi PL, , and Stevens VC: Prevention of mammary tumours with a chimeric Her-2 B-cell epitope peptide vaccine. Cancer Res, 2000; 60:3782\u20133789.","journal-title":"Cancer Res"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.02.026"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.170.8.4242"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2010.07.037"}],"container-title":["Monoclonal Antibodies in Immunodiagnosis &amp; Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/mab.2014.0092","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/mab.2014.0092","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/mab.2014.0092","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T20:17:26Z","timestamp":1777666646000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.1089\/mab.2014.0092"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["10.1089\/mab.2014.0092"],"URL":"https:\/\/doi.org\/10.1089\/mab.2014.0092","relation":{},"ISSN":["2167-9436","2167-9436"],"issn-type":[{"value":"2167-9436","type":"print"},{"value":"2167-9436","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6]]}}}